(2S,5S)-2,5-二甲基吡咯烷盐酸盐 | 138133-34-3

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2S,5S)-2,5-二甲基吡咯烷盐酸盐
• 中文别名: (2S,5S)-2,5-二甲基吡咯烷
• 英文名称: (2S,5S)-2,5-dimethylpyrrolidine hydrochloride
• 英文别名: (2S,5S)-2,5-Dimethylpyrrolidine hydrochloride；(2S,5S)-2,5-dimethylpyrrolidine;hydrochloride
• CAS: 138133-34-3
• 化学式: C₆H₁₃N*ClH
• 分子量: 135.637
• InChiKey: AFHNFHHYTYQLIO-GEMLJDPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (2S,5S)-2,5-二甲基吡咯烷盐酸盐 在 盐酸 、 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (2S)-2-[(trans-(2S,5S)-2,5-dimethyl-1-pyrrolidinyl)methyl]pyrrolidine
  参考文献：
  名称：

  New Catalysts for the Base-Promoted Isomerization of Epoxides to Allylic Alcohols. Broadened Scope and Near-Perfect Asymmetric Induction

  摘要：

  Optically active (1S,3R,4R)-3-[N-(trans-2,5-dialkyl)pyrrolidinyl]methyl-2-azabicyclo-[2.2.1]heptanes were evaluated as catalysts for the enantioselective beta-elimination of meso-epoxides. The (2R,5R)-dimethylpyrrolidinyl-substituted catalyst 4 exhibited exceptionally high enantioselectivity and reactivity, and several substrates were rearranged with enantioselectivities of 98-99% ee. In addition, the use of 4 allowed the first successful, true catalytic rearrangement of the difficult substrates cyclopentene oxide (81%, 96% ee) and (Z)-4-octene oxide (80%, 91% ee).

  DOI：

  10.1021/jo010934l
• 作为产物：
  描述：

  ((R)-1-Methyl-pent-4-enyl)-carbamic acid benzyl ester 在 盐酸 、 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 (2S,5S)-2,5-二甲基吡咯烷盐酸盐
  参考文献：
  名称：

  （+）或（-）反式-2,5-二甲基吡咯烷的合成

  摘要：

  从D或L-丙氨酸开始，以有效且合理的简短反应顺序，制备任一光学系列的反式-2,5-二甲基吡咯烷。

  DOI：

  10.1016/s0040-4039(00)96049-0

文献信息

• [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019049061A1

  公开（公告）日：2019-03-14

  The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言，本发明涉及根据公式(lb)的化合物，其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义；或其盐，包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白（c-MYC）和/或抑制p300/CBP组蛋白乙酰转移酶，可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、银屑病、银屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症，以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物，降低细胞中MYC蛋白（c-MYC）和抑制p300/CBP组蛋白乙酰转移酶活性的方法，以及治疗与之相关的疾病的方法。
• Discovery of an MLLT1/3 YEATS Domain Chemical Probe
  作者：Moses Moustakim、Thomas Christott、Octovia P. Monteiro、James Bennett、Charline Giroud、Jennifer Ward、Catherine M. Rogers、Paul Smith、Ioanna Panagakou、Laura Díaz-Sáez、Suet Ling Felce、Vicki Gamble、Carina Gileadi、Nadia Halidi、David Heidenreich、Apirat Chaikuad、Stefan Knapp、Kilian V. M. Huber、Gillian Farnie、Jag Heer、Nenad Manevski、Gennady Poda、Rima Al-awar、Darren J. Dixon、Paul E. Brennan、Oleg Fedorov

  DOI：10.1002/anie.201810617

  日期：2018.12.10

  YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine-binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small-molecule chemical probe, SGC-iMLLT, for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). SGC-iMLLT is a potent and

  包含YEATS域（YD）的蛋白质是药物发现中新兴的表观遗传学目标。这些修饰的赖氨酸结合蛋白的失调与癌症的发生和发展有关。我们在此报告了针对MLLT1（ENL / YEATS1）和MLLT3（AF9 / YEATS3）的YD的第一个小分子化学探针SGC-iMLLT的发现和表征。SGC-iMLLT是一种有效且选择性的MLLT1 / 3-组蛋白相互作用抑制剂。观察到对其他人类YD蛋白（YEATS2 / 4）和溴结构域具有出色的选择性。此外，我们的探针显示了MLLT1和MLLT3的细胞靶标接合。还报道了具有MLLT1 YD的第一个小分子X射线共晶体结构。
• Daphniphyllum alkaloids. 13. Asymmetric total synthesis of (-)-secodaphniphylline
  作者：Clayton H. Heathcock、Jeffrey A. Stafford

  DOI：10.1021/jo00035a010

  日期：1992.4

  (-)-Secodaphniphylline (1) has been prepared by total synthesis. The early stages of the synthesis were an asymmetric version of the previously published synthesis of methyl homosecodaphniphyllate (2). The necessary chirality was secured by an asymmetric Michael addition reaction of the lithium enolate of the C2-symmetric amide 9 to alpha,beta-unsaturated ester 10 to give ester amide 12. The conversion of 12 into (-)-2 was modelled after the previously reported synthesis in the analogous racemic series, although there were quantitative differences in the reaction conditions required for some of the succeeding transformations of the relatively hindered 2,5-dimethylpyrrolidine amides. The (-)-2 produced in this synthesis was of 84% ee, which represents the enantioselectivity of the initial Michael addition. Recrystallization of this material provided (-)-2 of 90% ee. The required 2,8-dioxabicyclo[3.2.1]octanecarboxylic acid chloride 5 was assembled in an eight-step synthesis starting with acid 18. The necessary chirality was acquired by an asymmetric reduction of acetylenic ketone 19 with the LiAlH4-Darvon alcohol complex. Alcohol 20, of 92% ee, was obtained and was isomerized to isomer 21 without loss of enantiomeric purity. Concomitant hydration of the triple bond, hydrolysis of the ketal, and cyclization of the resulting keto triol provided a 5:1 mixture of alcohols 23 and 24. After conversion to a similar mixture of methyl esters 25 and 26, the isomers were separated and the major carboxylic acid 27 was converted into acid chloride 5. Ester (-)-2 and acid chloride 5 were joined by a mixed Claisen condensation and the resulting diastereomeric beta-keto esters demethylated and decarboxylated by treatment with NaCN in hot DMSO to obtain (-)-secodaphniphylline (1). Although the two components in the Claisen reaction were enantiomerically enriched only to a modest extent (90% ee and 92% ee), the product alkaloid was > 99% ee.

  (-)-Secodaphniphylline（1）已通过全合成制得。合成的早期阶段是之前报道的甲基同-sec-daphniphyllate（2）合成方法的不对称版本。所需的手性通过C2对称酰胺9的锂烯醇与α,β-不饱和酯10的不对称迈克尔加成反应获得，生成酯酰胺12。12向(-)-2的转化参考了之前报道的相同非对映异构系列中的合成方法，尽管在后续变换中，特别是对于相对受阻的2,5-二甲基吡咯烷酰胺，所需反应条件存在定量差异。在这种合成中获得的(-)-2的对映体过量（ee）为84%，这代表了初始迈克尔加成的对映选择性。对该材料的重结晶提供了90% ee的(-)-2。所需的2,8-二氧双环[3.2.1]辛烷羧酸氯化物5是通过从酸18开始的八步合成组装而成。所需的手性通过不对称还原乙炔酮19来获得，使用LiAlH4-Darvon醇复合物。获得的醇20具有92%的ee，并被异构化为等构体21而不损失对映体纯度。同时水合三键、裂解酮以及酮醇的环化产生5:1的醇23和24的混合物。在转化为甲基酯25和26的类似混合物后，将异构体分离，并将主要羧酸27转化为酸氯化物5。酯(-)-2和酸氯化物5通过混合Claisen凝缩连接，所得的对映异构β-酮酯在NaCN和高温DMSO处理下脱甲基化和脱羧化，获得(-)-secodaphniphylline（1）。尽管Claisen反应的两个组分仅具有适度的对映体过量（90% ee和92% ee），但所得生物碱的对映体纯度仍超过99%。
• KRAS G12C inhibitors and methods of using the same
  申请人：Amgen Inc.

  公开号：US11090304B2

  公开（公告）日：2021-08-17

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了 KRAS G12C 抑制剂、其组合物以及使用方法。这些抑制剂可用于治疗多种疾病，包括胰腺癌、结直肠癌和肺癌。
• [EN] SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTE DE FAIBLE MASSE MOLÉCULAIRE DU RÉCEPTEUR B1 DE LA BRADYKININE
  申请人：JERINI AG

  公开号：WO2009036996A3

  公开（公告）日：2009-06-18